drugset / Trial / NCT02042807
To Evaluate the Effect of MCS® in Prostate Cancer Prevention
RandomizedParallel-groupTriple-blindPrevention
Summary
To evaluate the effect of MCS® compared with placebo in reducing the risk of biopsy-detectable prostate cancer in high-risk subjects after 104 weeks (24 months) of treatment.
Timeline
- Start
- 2014-10
- Primary completion
- 2024-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | MCS® | Unknown | 15 mg | — |
| Comparator | MCS® | Unknown | 30 mg | — |